Trial Information

Summary: SCORE Study: A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate.

Status: Recruiting

Protocol Number: MA21056

Sponsor: Hoffmann-La Roche

Company Division: Pharmaceutical

Official Scientific Title: A randomized, placebo controlled, multicenter clinical study investigating efficacy of rituximab (Mabthera/Rituxan) in the inhibition of joint structural damage assessed by magnetic resonance imaging in patients with rheumatoid arthritis and inadequate response to methotrexate - the R.A. SCORE stud

Brief Summary: This 3 arm study will assess the efficacy of MabThera in the prevention of progression of structural joint damage in patients with active rheumatoid arthritis who have an inadequate clinical response to methotrexate. Patients will be randomized to receive MabThera 1000mg i.v., MabThera 500mg i.v. or placebo i.v. on days 1 and 15; all patients will receive concomitant methotrexate at a stable dosage of 12.5-25mg/week throughout the study. Further courses of MabThera will be provided to eligible patients. Structural joint damage will be assessed by magnetic resonance imaging (MRI) at baseline, and at intervals during the study. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals. Target sample size is 180.

Study Phase: III

Study Design / Study Details:

• Purpose: Treatment
• Allocation: Randomized
• Masking: Double Blind
• Control: Placebo
• Assignment: Parallel
• Endpoints: Safety/Efficacy

Study Type:

Condition: Rheumatoid Arthritis

Intervention Type: Drug

Intervention Name: rituximab [MabThera/Rituxan]

Primary Outcome: 1. Changes in MRI bone erosion score from baseline Time frame: Week 24

Key Secondary Outcomes: 1. Change from baseline in MRI erosion, synovitis and osteitis Time frame: Week 12, 24 and 52 2. DAS 28-CRP, ACR 20/50/70, and HAQ. Time frame: Week 24 and 52 3. AEs, laboratory parameters, C-reactive protein, ESR. Time frame: Throughout study

Inclusion Criteria:

Exclusion Criteria:

Gender: Males or Females

Age Limits: Min: 18 Years Max: 80 Years

Accepts Healthy Volunteers: No

Anticipated Start Date: November, 2007

Trial Registration Date: 12/19/2007

Date Last Updated: 09/19/2008

Link To Trial Results

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: October 6, 2008 at 2:58:27 PM